GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by GlaxoSmithKline Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
As per attachment
Audio / Video · 05 Nov 2026, 3:42 am
GlaxoSmithKline Pharmaceuticals Discloses Audio Recording of Analyst and Institutional Investor Meet GlaxoSmithKline Pharmaceuticals Limited has informed BSE and NSE that, pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the audio recording of its Analyst and Institutional Investor Meet conducted on 4th Nov'26 has been uploaded on the company's official website.
Analyst meet Presentation
Intimation · 04 Nov 2026, 6:38 pm
GSK Pharmaceuticals Reports Strong Q2 FY27 Financial and Operational Performance GSK Pharmaceuticals delivered standalone Q2 FY27 revenue of ₹1,180cr (+21% YoY) and H1 revenue of ₹2,104cr (+18% YoY). EBITDA grew 20% YoY to ₹400cr (34% margin, -50 bps YoY), while PAT surged 33% YoY to ₹335cr (29% margin), aided by income tax refund interest; Q2 EPS rose 32% to ₹19.76. Growth was driven by general medicines (Augmentin, Calpol) and doubled Shingrix sales, lifting the innovation portfolio to 7% of revenue versus 3% in prior year. GSK maintained 25% share in its represented market.
As per attachment
Press Release · 04 Nov 2026, 12:32 am
GSK India Reports Strong Q2 FY27 With PAT Up 31% YoY GlaxoSmithKline Pharmaceuticals reported revenue of INR 1,180 crore for Q2 FY27 ended 30th Sep'26, up 21% YoY, supported by General Medicines, Vaccines, and Specialty portfolios alongside a favorable base effect. EBITDA rose 20% YoY, while PAT increased 31% YoY to INR 335 crore. Core brands Augmentin, Calpol, Ceftum, and T-bact gained market share, while Shingrix drove adult vaccine growth. The company announced its entry into haemato-oncology with the planned launch of BLENREP for relapsed or refractory multiple myeloma, building on its existing oncology footprint.
As per attachment
Change in Auditor · 04 Nov 2026, 12:31 am
GSK Pharmaceuticals Reports Q2 FY27 Consolidated Results and Leadership Changes GlaxoSmithKline Pharmaceuticals reported consolidated revenue from operations of ₹1,183.57 crore for the quarter ended 30th Sep'26, up 20.78% YoY from ₹979.94 crore. Consolidated net profit rose 30.44% YoY to ₹335.88 crore, supported by other income of ₹72.78 crore (including ₹42.09 crore interest on tax refund). Diluted EPS stood at ₹19.83. Additionally, the board approved the appointment of Sandeep Seth as Head – Ethics & Compliance and proposed Walker Chandiok & Co LLP as Statutory Auditors for five years starting FY28.
As per attachment
Change in Management · 04 Nov 2026, 12:30 am
GSK Pharma Q2 FY27 Results and Key Leadership and Auditor Changes GlaxoSmithKline Pharmaceuticals reported consolidated Q2 revenue from operations of Rs 1,18,357 lakhs for the quarter ended 30th Sep'26, up 20.8% YoY from Rs 97,994 lakhs and 26.1% QoQ from Rs 93,844 lakhs. Consolidated net profit rose 30.4% YoY and 41.6% QoQ to Rs 33,588 lakhs, delivering EPS of Rs 19.83. Additionally, the Board appointed Sandeep Seth as Head - Ethics & Compliance effective 3rd Nov'26, and approved M/s Walker Chandiok & Co LLP as statutory auditors for five years starting FY28, subject to shareholder approval.
outcome of Meeting
Financial Result · 04 Nov 2026, 12:27 am
GSK Pharmaceuticals Reports Q2 Results and Key Leadership Appointments GlaxoSmithKline Pharmaceuticals reported consolidated revenue of ₹1,183.57 crore for the quarter ended 30th Sep'26, up 20.8% YoY from ₹979.94 crore. Net profit grew 30.4% YoY to ₹335.88 crore, compared to ₹257.49 crore in the prior-year period, supported by ₹72.78 crore in other income (including ₹42.09 crore tax refund interest). Basic EPS stood at ₹19.83. The board approved the appointment of Sandeep Seth as Head - Ethics & Compliance and proposed Walker Chandiok & Co LLP as Statutory Auditors for five years starting FY28.
GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 04 Nov 2026, 12:19 am
GlaxoSmithKline Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 1,18,357 (+20.8% YoY | +26.1% QoQ) ■ EBITDA: 40,207 (+19.8% YoY | +36.1% QoQ) ■ EBITDA Margin (%): 34.0 (-29 bps YoY | +248 bps QoQ) ■ PAT: 33,588 (+30.4% YoY | +41.6% QoQ) ■ EPS (INR): 19.8 (+31.6% YoY | +41.6% QoQ)
Outcome of meeting
Outcome · 04 Nov 2026, 12:18 am
As per attachment
Intimation · 28 Oct 2026, 9:58 pm
GSK Pharmaceuticals Schedules Digital Analyst and Institutional Investor Meet GlaxoSmithKline Pharmaceuticals Limited has scheduled a group analyst and institutional investor meeting on 4th Nov'26 via a digital platform, in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. The company stated that only publicly available information will be shared during the interaction, with meeting dates subject to change based on exigencies.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 03 Nov 2026, 5:30 am
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 03 Nov 2026, 5:30 am
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve As per attachment
Intimation · 03 Nov 2026, 5:30 am
GlaxoSmithKline Pharmaceuticals Schedules Board Meeting for Q2 Results GlaxoSmithKline Pharmaceuticals Limited will hold a Board of Directors meeting on 3rd Nov'26 to consider, approve, and take on record the un-audited financial results for the second quarter and half year ended 30th Sep'26, pursuant to Regulations 29 and 33 of SEBI LODR Regulations.
As per attachment
Others (Uncategorized) · 26 Aug 2026, 8:09 pm
GSK Pharma Clarifies Trading Volume Spike is Market-Driven On 26th Aug'26, GlaxoSmithKline Pharmaceuticals addressed a stock exchange query regarding a significant increase in its trading volume. The company confirmed it has made all required disclosures under SEBI (LODR) Regulations and has not withheld any material, price-sensitive information. Management stated the volume surge is "purely market driven" and reiterated its commitment to ongoing compliance with listing regulations. No undisclosed corporate event or operational change is responsible for the increased trading activity.
The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Ltd on August 26, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Others (Uncategorized) · 26 Aug 2026, 7:33 pm
As per attachment
Others (Uncategorized) · 19 Aug 2026, 10:56 pm
GSK Pharma Receives Rs 4.99 Crore Tax Refund for AY26 GlaxoSmithKline Pharmaceuticals received an intimation u/s 143(1) of the Income Tax Act for a tax refund of Rs 4.99 crores for the assessment year 2025-2026. The company received the intimation on 19th Aug'26 and the refund amount was credited to its bank account on 18th Aug'26. The refund will be accounted for in the Tax Paid Assets account on the Balance Sheet. This event is a positive, one-time cash inflow for the company but has a minor financial impact.
Transcript
Transcript · 07 Aug 2026, 1:21 am
GSK Pharma Q1 FY27: Innovation and Vaccines Drive Strong Growth and Margin Expansion GSK Pharma reported strong Q1 FY27 results, with sales at INR924 crores, up 15% YoY, and PAT growing 24% to INR253 crores. Adjusted for a favorable base, sustainable growth was 9-10%. The innovation portfolio's contribution to revenue doubled to 7%, driven by oncology and vaccines. Shingrix vaccine sales surged 65% YoY, crossing INR100 crores on a MAT basis. EBITDA margin improved by 50 bps to 17%, while PAT margin expanded 200 bps to 27.6%, aided by a one-off dividend. The company maintains its growth outlook.
IT Refund of Rs 52 crores
Others (Uncategorized) · 07 Aug 2026, 1:17 am
GSK Pharma receives tax refund, booking interest income GlaxoSmithKline Pharmaceuticals received a final order from the ACIT resulting in a tax refund of Rs 52.00 Cr on 6th Aug'26. This refund pertains to the assessment year 1984-85 and follows an OGE to CIT-Appeal received on 27th Jan'26. The company will credit interest income of Rs 42.09 Cr related to this refund to its Profit & Loss account. The initial demand liability cited in the order was Rs 23.21 Cr.
As per attachment
Audio / Video · 05 Aug 2026, 8:34 pm
GSK Pharma Discloses Analyst and Investor Meeting Presentation Recording GlaxoSmithKline Pharmaceuticals Limited announced on 5th Aug'26 that the recording of its recent analyst and institutional investor meetings is now available. The company has uploaded the presentation video file to its investor relations website, in compliance with SEBI's Listing Obligations and Disclosure Requirements regulations. The link provides access to the materials and discussions from the event.
As per attachment
Audio / Video · 04 Aug 2026, 2:14 am
GSK Pharma Uploads Analyst/Investor Meeting Recording GlaxoSmithKline Pharmaceuticals Limited filed a notice on 3rd Aug'26, informing stock exchanges about the outcome of its recent analyst and institutional investor meetings. In compliance with SEBI's listing regulations, the company has uploaded an audio recording of the proceedings. The recording is available on the company's investor relations website for shareholder access.
Reappointment of Managing Director
Change in Management · 03 Aug 2026, 9:44 pm
GSK Q1FY27 Results: Strong YoY Profit Growth Amid Management Changes For Q1FY27 ending 30th Jun'26, GlaxoSmithKline Pharmaceuticals reported a 23.8% YoY increase in standalone net profit to Rs. 253.3 crore, with revenue from operations growing 14.9% YoY to Rs. 924.4 crore. However, profit declined 7.9% QoQ. The Board announced key management changes: Karine J F Natland was appointed as Non-Executive Director effective 3rd Aug'26, succeeding Subesh Williams. Additionally, Bhushan Akshikar was re-appointed as Managing Director for a two-year term starting 1st Dec'26, ensuring leadership continuity.
As per attachment
Change in Management · 03 Aug 2026, 9:42 pm
GSK India Q1'27 PAT Rises 24%, Board Undergoes Key Leadership Changes GlaxoSmithKline's standalone PAT for the quarter ended 30-Jun-26 grew 23.8% YoY to ₹253.3 crore, while revenue from operations increased 14.9% YoY to ₹924.4 crore. However, PAT declined 7.9% QoQ from ₹274.9 crore. The Board appointed Ms. Karine Natland as Non-Executive Director and re-appointed Mr. Bhushan Akshikar as Managing Director for two years from 01-Dec-26. Mr. Subesh Williams stepped down as Non-Executive Director effective 03-Aug-26. Basic EPS for the quarter stood at ₹14.95, up from ₹12.08 YoY.
As per attachment
Change in Management · 03 Aug 2026, 9:41 pm
GSK Q1 FY27 Results: Strong Profit Growth and Key Board Changes GlaxoSmithKline Pharma reported a standalone net profit of ₹253.33 Cr for the quarter ended 30-Jun'26, a 23.7% YoY increase. Revenue from operations grew 14.9% YoY to ₹924.42 Cr, though it declined 6.5% QoQ. PBT stood at ₹337.98 Cr, up 21.3% YoY. The Board announced the appointment of Ms. Karine J F Natland as a Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director. Mr. Subesh Williams stepped down as a Non-Executive Director effective 03-Aug'26.
As per attachment
Press Release · 03 Aug 2026, 9:40 pm
GSK India Reports Strong Q1FY27 with 24% PAT Growth GlaxoSmithKline Pharmaceuticals posted strong Q1FY27 results for the quarter ended 30th Jun'26, driven by growth across its core and innovative portfolios. Revenue grew 15% YoY to INR 924 crores, while Profit After Tax (PAT) increased 24% YoY to INR 253 crores. EBITDA margins stood at 32%. Growth was broad-based, with strong performance from the General Medicines, Vaccines, and Oncology businesses. Key brands like Augmentin, Ceftum, and Shingrix contributed significantly. The company is preparing for upcoming launches including Blenrep and Arexvy.
Presentation
Intimation · 03 Aug 2026, 9:30 pm
GSK Pharma Q1 FY27: Strong Revenue Growth and Margin Expansion GSK India reported robust Q1 FY27 results with revenue at ₹924cr (+15% YoY) and PAT at ₹253cr (+24% YoY). Growth was driven by general medicines like Augmentin and Ceftum, along with a 65% sales increase in Shingrix. The innovation portfolio, including oncology and new vaccines, contributed 7% of total sales. EBITDA margin expanded 50 bps YoY to 31.7% due to a 150 bps improvement in gross margin. PAT margin improved by 200 bps to 27.6%, aided by a one-off dividend. EPS grew 24% to ₹14.95.
Outcome of meeting
Financial Result · 03 Aug 2026, 9:18 pm
GSK India Q1FY27 Net Profit Rises 24% YoY; Key Board Changes Announced GSK India reported standalone net profit of ₹253.3 cr for Q1FY27, up 23.8% YoY but down 7.9% QoQ. Revenue from operations grew 14.9% YoY to ₹924.4 cr. The Board approved the appointment of Ms. Karine J F Natland as a Non-Executive Director, replacing Mr. Subesh Williams who resigned on 3rd Aug'26. Mr. Bhushan Akshikar was also re-appointed as Managing Director for a two-year term starting 1st Dec'26. Other income included a ₹180 cr dividend from its subsidiary, Biddle Sawyer Limited.